Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Revenue (2022 - 2025)

Historic Revenue for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to $437602.0.

  • 60 Degrees Pharmaceuticals' Revenue rose 22344.76% to $437602.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $943721.0, marking a year-over-year increase of 9196.15%. This contributed to the annual value of $607574.0 for FY2024, which is 13960.52% up from last year.
  • As of Q3 2025, 60 Degrees Pharmaceuticals' Revenue stood at $437602.0, which was up 22344.76% from $100932.0 recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Revenue ranged from a high of $437602.0 in Q3 2025 and a low of -$37174.0 during Q4 2022
  • Moreover, its 4-year median value for Revenue was $115323.0 (2024), whereas its average is $124244.1.
  • In the last 5 years, 60 Degrees Pharmaceuticals' Revenue tumbled by 6956.45% in 2023 and then skyrocketed by 51538.55% in 2024.
  • 60 Degrees Pharmaceuticals' Revenue (Quarter) stood at -$37174.0 in 2022, then surged by 438.09% to $125681.0 in 2023, then soared by 92.26% to $241635.0 in 2024, then skyrocketed by 81.1% to $437602.0 in 2025.
  • Its last three reported values are $437602.0 in Q3 2025, $100932.0 for Q2 2025, and $163552.0 during Q1 2025.